Economic evaluation of cemiplimab plus chemotherapy regimen for advanced non-small-cell lung cancer

Cemiplimab, a novel PD-1 inhibitor, exhibits significant antitumor activity against advanced non-small cell lung cancer (NSCLC). However, the cost-effectiveness of this drug for the treatment remains unclear. ...

Source: BMC Cancer - February 21, 2024 Category: Cancer & Oncology Authors: Yitian Lang, Yan Lin, Meng Deng and Xiaoyan Liu Tags: Research Source Type: research